Replies to post #113138 on Biotech Values

[RockRat]

>>those are examples but not limited to..<<

Understood, but our speculations based on unspecified examples are going to be even less informed. I'm happy to entertain well-reasoned ones, though. The reason I pointed to #2 is because, as has been pointed out here, the manufacturing practices are a much harder area to optimize with a mixture like Lovenox versus your standard small molecule generic. GMP here could be the ultimate bin for all sorts of underlying problems. Or not.

Regards, RockRat

[HattieTheWitch]

What's that phrase? Occam's razor?

If TEVA's issue(s) (as idenfied by the FDA) were all that minor, why wouldn't they simply say what they are? For a company that seems to place so much emphasis on PR, it seems an obvious question.

TEVA's unwillingness to do so seems like more of the same.

But, wthdik?